Back to results
US 2012/0070430 A1Published application
Identification of tumor-associated markers for diagnosis and therapy
OwnerUgur Sahin, Ozlem Tureci +1inventors
InventorsUgur Sahin, Ozlem Tureci, Michael Koslowski
Life of this patent
Estimating the term…
Abstract
The invention relates to genetic products the expression of which is associated with cancer diseases. The invention also relates to the therapy and diagnosis of diseases in which the genetic products are expressed or aberrantly expressed, in particular cancer diseases.
Claims39
A pharmaceutical composition, comprising an agent which
- (I) inhibits expression or activity of a tumor-associated antigen and/or
- (II) has tumor-inhibiting activity, and is selective for cells expressing or abnormally expressing a nucleic acid coding for a tumor-associated antigen or a tumor-associated antigen and/or
- (III) when administered, selectively increases the amount of complexes between an MHC molecule and a tumor-associated antigen or a part thereof,
- said tumor-associated antigen having a sequence encoded by a nucleic acid which is selected from the group consisting of:
- (a) a nucleic acid which comprises a nucleic acid sequence selected from the group consisting of SEQ ID NOs:
- 634, 1-540, 541, 545, 549, 553, 557, 560, 563, 566, 570, 574, 577, 580, 583, 587, 591, 595, 599, 602, 606, 610, 613, 617, 620, 624, 638, 642, 646, 649, 653, 656, 660, 664, 668, 671, 675, 679, 682, and 686, a part or derivative thereof,
- (b) a nucleic acid which hybridizes with the nucleic acid of (a) under stringent conditions,
- (c) a nucleic acid which is degenerate with respect to the nucleic acid of (a) or (b), and
- (d) a nucleic acid which is complementary to the nucleic acid of (a), (b) or (c).
6 more elements
A pharmaceutical composition, comprising one or more components selected from the group consisting of:
- (i) a tumor-associated antigen or a part thereof,
- (ii) a nucleic acid which codes for a tumor-associated antigen or a part thereof,
- (iii) an antibody which binds to a tumor-associated antigen or a part thereof,
- (iv) an antisense nucleic acid which hybridizes specifically with a nucleic acid coding for a tumor-associated antigen,
- (v) an siRNA directed against a nucleic acid coding for a tumor-associated antigen,
- (vi) a host cell which expresses a tumor-associated antigen or a part thereof, and
- (vii) isolated complexes between a tumor-associated antigen or a part thereof and an MHC molecule,
- said tumor-associated antigen having a sequence encoded by a nucleic acid which is selected from the group consisting of:
- (a) a nucleic acid which comprises a nucleic acid sequence selected from the group consisting of SEQ ID NOs:
- 634, 1-540, 541, 545, 549, 553, 557, 560, 563, 566, 570, 574, 577, 580, 583, 587, 591, 595, 599, 602, 606, 610, 613, 617, 620, 624, 638, 642, 646, 649, 653, 656, 660, 664, 668, 671, 675, 679, 682, and 686, a part or derivative thereof,
- (b) a nucleic acid which hybridizes with the nucleic acid of (a) under stringent conditions,
- (c) a nucleic acid which is degenerate with respect to the nucleic acid of (a) or (b), and
- (d) a nucleic acid which is complementary to the nucleic acid of (a), (b) or (c).
10 more elements
A method of diagnosing or monitoring a cancer disease, which method comprises detecting or determining the quantity
- (i) of a tumor-associated nucleic acid or of a part thereof, and/or
- (ii) of a tumor-associated antigen or of a part thereof, and/or
- (iii) of an antibody to the tumor-associated antigen or a part thereof and/or
- (iv) of T lymphocytes which are specific to the tumor-associated antigen or to a part thereof
- in a biological sample isolated from a patient,
- said tumor-associated nucleic acid being selected from the group consisting of:
- (a) a nucleic acid which comprises a nucleic acid sequence selected from the group consisting of SEQ ID NOs:
- 634, 1-540, 541, 545, 549, 553, 557, 560, 563, 566, 570, 574, 577, 580, 583, 587, 591, 595, 599, 602, 606, 610, 613, 617, 620, 624, 638, 642, 646, 649, 653, 656, 660, 664, 668, 671, 675, 679, 682, and 686, a part or derivative thereof,
- (b) a nucleic acid which hybridizes with the nucleic acid of (a) under stringent conditions,
- (c) a nucleic acid which is degenerate with respect to the nucleic acid of (a) or (b), and
- (d) a nucleic acid which is complementary to the nucleic acid of (a), (b) or (c), and
- said tumor-associated antigen having a sequence encoded by a nucleic acid which is selected from said group of nucleic acids.
9 more elements
A method of treating, preventing, diagnosing or monitoring a disease characterized by expression or abnormal expression of a tumor-associated antigen, which method comprises administering an antibody binding to said tumor-associated antigen or to a part thereof and coupled to a therapeutic or diagnostic agent,
- said tumor-associated antigen having a sequence encoded by a nucleic acid which is selected from the group consisting of:
- (a) a nucleic acid which comprises a nucleic acid sequence selected from the group consisting of SEQ ID NOs:
- 634, 1-540, 541, 545, 549, 553, 557, 560, 563, 566, 570, 574, 577, 580, 583, 587, 591, 595, 599, 602, 606, 610, 613, 617, 620, 624, 638, 642, 646, 649, 653, 656, 660, 664, 668, 671, 675, 679, 682, and 686, a part or derivative thereof,
- (b) a nucleic acid which hybridizes with the nucleic acid of (a) under stringent conditions,
- (c) a nucleic acid which is degenerate with respect to the nucleic acid of (a) or (b), and
- (d) a nucleic acid which is complementary to the nucleic acid of (a), (b) or (c).
3 more elements
A method of treating a patient having a disease characterized by expression or abnormal expression of a tumor-associated antigen, which method comprises:
- (i) providing a sample containing immunoreactive cells,
- (ii) contacting said sample with a host cell expressing said tumor-associated antigen or a part thereof, under conditions which favor production of cytolytic or cytokine-releasing T cells against said tumor-associated antigen or said part thereof, and
- (iii) introducing the cytolytic or cytokine-releasing T cells into the patient in an amount suitable for lysing cells expressing the tumor-associated antigen or a part thereof,
- said tumor-associated antigen having a sequence encoded by a nucleic acid which is selected from the group consisting of:
- (a) a nucleic acid which comprises a nucleic acid sequence selected from the group consisting of SEQ ID NOs:
- 634, 1-540, 541, 545, 549, 553, 557, 560, 563, 566, 570, 574, 577, 580, 583, 587, 591, 595, 599, 602, 606, 610, 613, 617, 620, 624, 638, 642, 646, 649, 653, 656, 660, 664, 668, 671, 675, 679, 682, and 686, a part or derivative thereof,
- (b) a nucleic acid which hybridizes with the nucleic acid of (a) under stringent conditions,
- (c) a nucleic acid which is degenerate with respect to the nucleic acid of (a) or (b), and
- (d) a nucleic acid which is complementary to the nucleic acid of (a), (b) or (c).
6 more elements
An agent, which binds specifically to a protein or polypeptide or to a part thereof, said protein or polypeptide being encoded by a nucleic acid selected from the group consisting of:
- (a) a nucleic acid which comprises a nucleic acid sequence selected from the group consisting of SEQ ID NOs:
- 634, 1-540, 541, 545, 549, 553, 557, 560, 563, 566, 570, 574, 577, 580, 583, 587, 591, 595, 599, 602, 606, 610, 613, 617, 620, 624, 638, 642, 646, 649, 653, 656, 660, 664, 668, 671, 675, 679, 682, and 686, a part or derivative thereof,
- (b) a nucleic acid which hybridizes with the nucleic acid of (a) under stringent conditions,
- (c) a nucleic acid which is degenerate with respect to the nucleic acid of (a) or (b), and
- (d) a nucleic acid which is complementary to the nucleic acid of (a), (b) or (c).
2 more elements
An antibody, which binds selectively to a complex of:
- (i) a protein or polypeptide or a part thereof and
- (ii) an MHC molecule to which said protein or polypeptide or said part thereof binds,
- with said antibody not binding to (i) or (ii) alone and said protein or polypeptide being encoded by a nucleic acid selected from the group consisting of:
- (a) a nucleic acid which comprises a nucleic acid sequence selected from the group consisting of SEQ ID NOs:
- 634, 1-540, 541, 545, 549, 553, 557, 560, 563, 566, 570, 574, 577, 580, 583, 587, 591, 595, 599, 602, 606, 610, 613, 617, 620, 624, 638, 642, 646, 649, 653, 656, 660, 664, 668, 671, 675, 679, 682, and 686, a part or derivative thereof,
- (b) a nucleic acid which hybridizes with the nucleic acid of (a) under stringent conditions,
- (c) a nucleic acid which is degenerate with respect to the nucleic acid of (a) or (b), and
- (d) a nucleic acid which is complementary to the nucleic acid of (a), (b) or (c).
5 more elements
A kit for detecting cancer, which kit comprises agents for detecting or determining the quantity
- (i) of a tumor-associated nucleic acid or of a part thereof, and/or
- (ii) of a tumor-associated antigen or of a part thereof, and/or
- (iii) of antibodies which bind to the tumor-associated antigen or to a part thereof, and/or
- (iv) of T cells which are specific for a complex between the tumor-associated antigen or a part thereof and an MHC molecule,
- said tumor-associated nucleic acid being selected from the group consisting of:
- (a) a nucleic acid which comprises a nucleic acid sequence selected from the group consisting of SEQ ID NOs:
- 634, 1-540, 541, 545, 549, 553, 557, 560, 563, 566, 570, 574, 577, 580, 583, 587, 591, 595, 599, 602, 606, 610, 613, 617, 620, 624, 638, 642, 646, 649, 653, 656, 660, 664, 668, 671, 675, 679, 682, and 686, a part or derivative thereof,
- (b) a nucleic acid which hybridizes with the nucleic acid of (a) under stringent conditions,
- (c) a nucleic acid which is degenerate with respect to the nucleic acid of (a) or (b), and
- (d) a nucleic acid which is complementary to the nucleic acid of (a), (b) or (c), and
- said tumor-associated antigen having a sequence encoded by a nucleic acid which is selected from said group of nucleic acids.
8 more elements
Dependencies are inferred from the claim text.